Abstract: The present invention discloses a catalytic hydrogenation method for carbon nine resin, comprising the following steps: 1) adding a Pt—W—Y/?-Al2O3 catalyst in the first half of a fixed bed, adding a Pd—Zr—Nd/?-Al2O3 catalyst in the second half of the fixed bed, and feeding hydrogen for reduction; and 2) catalytic hydrogenating the pretreated carbon nine resin in the fixed bed. In the present invention, different catalysts capable of reacting under the same catalytic conditions are added in the first and second halves of the fixed bed, and the two different catalysts play different roles, and can be active and complementary to each other under the same conditions. The synergistic effect of the two catalysts plays a good catalytic role. Moreover, the production process is simplified, and the production cost is saved.

Abstract: The described technology is generally directed towards interoperability between distributed units (DUs) and radio units (RUs) in a radio access network (RAN) network. Various embodiments are presented to enable automated determination and/or automated implementation of various configurations and functionalities on a physical random access channel (PRACH) between a DU and a RU. The automated operations presented herein enable a DU to discover and verify PRACH functionality (e.g., regarding PRACH time offset) supported by a RU and/or implementation of the PRACH functionality at the RU to enable interoperability between the DU and the RU, thereby satisfying the interoperability requirement of the O-RAN specification.

Abstract: An air guide ring for an air conditioner outdoor unit is provided. The air guide ring includes an air guide ring body. An air guide channel is defined in the air guide ring body. The air guide ring body includes a first limiting portion and a second limiting portion. The first limiting portion and the second limiting portion are configured to fit with a fixing member of the air conditioner outdoor unit and to implement bi-directional limiting, so as to prevent inward contraction deformation and outward expansion deformation of the air guide ring body from occurring.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.

Abstract: A socket connector includes a base formed of a conductive upper base part and a conductive lower base part which are affixed together, a conductive barrel seated within a passageway and a pocket formed by the base, at least one conductive biasing member engaging the base and the barrel, a conductive contact seated within the barrel, and an insulative housing in which the base is positioned. The housing is coupled to the base. At least one of the upper and lower base parts has a plurality of pins depending from the respective wall which seat within plated through holes of a printed circuit board. A coupling pin is mounted in the socket connector and is further coupled to an electrical component.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.

Abstract: Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.

Abstract: A compound, an organic electroluminescent device containing the compound, and an application thereof. The compound has a structure shown in (I).

Abstract: Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.

Abstract: Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.

Abstract: Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.

Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.